Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter May 16, 2022

Global perspective on pediatric growth hormone registries: a systematic review

  • Parisa Eslami ORCID logo , Fatemeh Sayarifard , Reza Safdari EMAIL logo , Leila Shahmoradi and Zahra Karbasi



Registries are considered valuable data sources for identification of pediatric conditions treated with growth hormone (GH), and their follow-up. Currently, there is no systematic literature review on the scope and characteristics of pediatric GH registries. Therefore, the purpose of this systematic review is to identify worldwide registries reported on pediatric GH treatment and to provide a summary of their main characteristics.


Pediatric GH registries were identified through a systematic literature review. The search was performed on all related literature published up to January 30th, 2021. Basic information on pediatric GH registries, their type and scope, purpose, sources of data, target conditions, reported outcomes, and important variables were analyzed and presented.


Twenty two articles, reporting on 20 pediatric GH registries, were included in this review. Industrial funding was the most common funding source. The main target conditions included in the pediatric GH registries were: growth hormone deficiency, Turner syndrome, Prader Willi syndrome, small for gestational age, idiopathic short stature, and chronic renal insufficiency. The main objectives in establishing and running pediatric GH registries were assessing the safety and effectiveness of the treatment, describing the epidemiological aspects of target growth conditions and populations, serving public health surveillance, predicting and measuring treatment outcomes, exploring new and useful aspects of GH treatment, and improving the quality of patient care.


This systematic review provides a global perspective on pediatric GH registries which can be used as a basis for the design and development of new GH registry systems at both national and international levels.

Corresponding author: Dr. Reza Safdari, Department of Health Information Management, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran, E-mail:

  1. Research funding: None declared.

  2. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  3. Competing interests: Authors state no conflict of interest.

  4. Informed consent: Not applicable.

  5. Ethical approval: The local Institutional Review Board deemed the study exempt from review.


1. Rogol, AD, Hayden, GF. Etiologies and early diagnosis of short stature and growth failure in children and adolescents. J Pediatr 2014;164:S1–14. e6. in Google Scholar PubMed

2. Collett-Solberg, PF, Jorge, AA, Boguszewski, MC, Miller, BS, Choong, CSY, Cohen, P, et al.. Growth hormone therapy in children; research and practice–a review. Growth Hormone IGF Res 2019;44:20–32. in Google Scholar PubMed

3. Ayyar, VS. History of growth hormone therapy. Indian J Endocrinol Metabol 2011;15(3 Suppl):S162. in Google Scholar PubMed PubMed Central

4. Kaplan, S, Underwood, L, August, G, Bell, J, Blethen, S, Brown, D, et al.. Clinical studies with recombinant-DNA-derived methionyl-human growth hormone in growth hormone-deficient children. In: Human growth hormone. Boston, MA: Springer; 1986:267–77 pp.10.1007/978-1-4615-7201-5_22Search in Google Scholar

5. Ranke, MB, Wit, JM. Growth hormone—past, present and future. Nat Rev Endocrinol 2018;14:285–300. in Google Scholar PubMed

6. Carel, JC, Ecosse, E, Landier, F, Meguellati-Hakkas, D, Kaguelidou, F, Rey, G, et al.. Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. J Clin Endocrinol Metab 2012;97:416–25. in Google Scholar PubMed

7. Bryant, J, Cave, C, Mihaylova, B, Chase, D, McIntyre, L, Gerard, K, et al.. Clinical and cost effectiveness of growth hormone in children. Health Technol Assess 2001;6:1–175. in Google Scholar PubMed

8. Lee, JM, Davis, MM, Clark, SJ, Hofer, TP, Kemper, AR. Estimated cost-effectiveness of growth hormone therapy for idiopathic short stature. Arch Pediatr Adolesc Med 2006;160:263–9. in Google Scholar PubMed

9. Biller, B, Vance, M, Kleinberg, D, Cook, D, Gordon, T. Clinical and reimbursement issues in growth hormone use in adults. Am J Manag Care 2000;6(15 Suppl):S817–27.Search in Google Scholar

10. Graber, E, Reiter, EO, Rogol, AD. Human growth and growth hormone: from antiquity to the recominant age to the future. Front Endocrinol 2021;12:1–19. in Google Scholar PubMed PubMed Central

11. Arnao, MDR, Sánchez, AR, García-Rey, C, Arroyo Díez, FJ, Estrada, RC, Cuartero, BG, et al.. The DATAC study: a new growth database. Description of the epidemiology, diagnosis and therapeutic attitude in a group of Spanish children with short stature. J Pediatr Endocrinol Metab 2014;27:1201–8. in Google Scholar PubMed

12. Ranke, MB, Price, DA, Reiter, EO. Growth hormone therapy in pediatrics: 20 years of KIGS. Basel, Switzerland: Karger Medical and Scientific Publishers; 2007.10.1159/isbn.978-3-318-01447-1Search in Google Scholar

13. Moher, D, Liberati, A, Tetzlaff, J, Altman, DG, Group, P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097. in Google Scholar

14. Thomas, M, Massa, G, Craen, M, de Zegher, F, Bourguignon, J-P, Heinrichs, C, et al.. Prevalence and demographic features of childhood growth hormone deficiency in Belgium during the period 1986–2001. Eur J Endocrinol 2004;151:67–72. in Google Scholar

15. Thomas, M, Beckers, D, Brachet, C, Dotremont, H, Lebrethon, M-C, Lysy, P, et al.. Adult height after growth hormone treatment at pubertal onset in short adolescents born small for gestational age: results from a Belgian registry-based study. Int J Endocrinol 2018;2018:6421243. in Google Scholar

16. Cowell, C, Dietsch, S, Greenacre, P. Growth hormone therapy for three years: the OZGROW experience. J Paediatr Child Health 1996;32:86–93. in Google Scholar

17. Werther, GA. Growth Hormone Database OZGROW TA. Growth hormone measurements vs. auxology in treatment decisions: the Australian experience. J Pediatr 1996;128:S47–51. in Google Scholar

18. Pricci, F, Villa, M, Maccari, F, Agazio, E, Rotondi, D, Panei, P, et al.. The Italian Registry of GH Treatment: electronic Clinical Report Form (e-CRF) and web-based platform for the national database of GH prescriptions. J Endocrinol Invest 2019;42:769–77. in Google Scholar PubMed PubMed Central

19. Chung, S, Yoo, JH, Choi, JH, Rhie, YJ, Chae, HW, Kim, JH, et al.. Design of the long-term observational cohort study with recombinant human growth hormone in Korean children: LG growth study. Ann Pediatr Endocrinol Metabol 2018;23:43–50. in Google Scholar PubMed PubMed Central

20. Savendahl, L, Maes, M, Albertsson-Wikland, K, Borgstrom, B, Carel, JC, Henrard, S, et al.. Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study. J Clin Endocrinol Metab 2012;97:E213–7. in Google Scholar PubMed

21. Höybye, C, Sävendahl, L, Christesen, HT, Lee, P, Pedersen, BT, Schlumpf, M, et al.. The NordiNet® International Outcome Study and NovoNet® ANSWER Program®: rationale, design, and methodology of two international pharmacoepidemiological registry-based studies monitoring long-term clinical and safety outcomes of growth hormone therapy (Norditropin®). J Clin Epidemiol 2013;5:119–27.10.2147/CLEP.S42602Search in Google Scholar PubMed PubMed Central

22. Bell, JJ, Lippe, B, Romano, AA, Cernich, JT, Swinford, RD, Moawad, D. National cooperative growth study: 25 years of growth hormone data, insights, and lessons for future registries. Pediatr Endocrinol Rev: PER 2018;16:240–55. in Google Scholar PubMed

23. Blethen, SL, O’Brien, F, Reinhart, R. An overview of the GHMonitor, a registry of children treated with Saizen somatropin [recombinant hGH for injection]. Pediatr Endocrinol Rev: PER 2005;2:324–6.Search in Google Scholar

24. Coutant, R, Munoz, JB, Dumitrescu, C, Schnabel, D, Sert, C, Perrot, V, et al.. Year-one effectiveness and overall safety of NutropinAq (R) for growth hormone deficiency (GHD) and other paediatric growth disorders: completion of the international cooperative growth study (iNCGS) European Registry. Horm Res Paediatr 2018;90:429–30.Search in Google Scholar

25. Bang, P, Polak, M, Woelfle, J, Houchard, A, Grp, EIRS. Effectiveness and safety of rhIGF-1 therapy in children: the European Increlex (R) growth forum database experience. Horm Res Paediatr 2015;83:345–57. in Google Scholar PubMed

26. Swerdlow, AJ, Cooke, R, Albertsson-Wikland, K, Borgström, B, Butler, G, Cianfarani, S, et al.. Description of the SAGhE Cohort: a large European Study of mortality and cancer incidence risks after childhood treatment with recombinant growth hormone. Horm Res Paediatr 2015;84:172–83. in Google Scholar PubMed PubMed Central

27. Child, CJ, Zimmermann, AG, Chrousos, GP, Cummings, E, Deal, CL, Hasegawa, T, et al.. Safety outcomes during pediatric GH therapy: final results from the prospective GeNeSIS observational program. J Clin Endocrinol Metab 2019;104:379–89. in Google Scholar PubMed PubMed Central

28. Ranke, MB, Dowie, J. KIGS and KIMS as tools for evidence-based medicine. Horm Res Paediatr 1999;51(1 Suppl):83–6. in Google Scholar PubMed

29. Ranke, MB, Lindberg, A, Board, KI. Observed and predicted total pubertal growth during treatment with growth hormone in adolescents with idiopathic growth hormone deficiency, Turner syndrome, short stature, born small for gestational age and idiopathic short stature: KIGS analysis and review. Horm Res Paediatr 2011;75:423–32. in Google Scholar PubMed

30. Wilton, P. Safety of growth hormone (GH)-value of a large data base. Clin Pediatr Endocrinol 1994;3(5 Suppl):61–71. in Google Scholar

31. Pfäffle, R, Schwab, KO, Marginean, O, Walczak, M, Szalecki, M, Schuck, E, et al.. Design of, and first data from, PATRO children, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope® in children requiring growth hormone treatment. Therapeut Adv Endocrinol Metabol 2013;4:3–11. in Google Scholar PubMed PubMed Central

32. Koledova, E, Stoyanov, G, Ovbude, L, Davies, PS. Adherence and long-term growth outcomes: results from the easypod™ connect observational study (ECOS) in paediatric patients with growth disorders. Endocr Connect 2018;7:914–23. in Google Scholar PubMed PubMed Central

33. Clayton, P, Chatelain, P, Tatò, L, Yoo, H, Ambler, G, Belgorosky, A, et al.. A pharmacogenomic approach to the treatment of children with GH deficiency or Turner syndrome. Eur J Endocrinol 2013;169:277. in Google Scholar

34. Avorn, J. In defense of pharmacoepidemiology—embracing the yin and yang of drug research. N Engl J Med 2007;357:2219–21. in Google Scholar

35. Williams, RJ, Tse, T, Harlan, WR, Zarin, DA. Registration of observational studies: is it time? Can Med Assoc J 2010;182:1638–42. in Google Scholar

36. Cronin, MJ. From the Division of Research Technology G. Pioneering recombinant growth hormone manufacturing: pounds produced per mile of height. J Pediatr 1997;131:S5–7. in Google Scholar

37. Coutant, R, Bosch Muñoz, J, Dumitrescu, CP, Schnabel, D, Sert, C, Perrot, V, et al.. Effectiveness and overall safety of NutropinAq® for growth hormone deficiency and other paediatric growth hormone disorders: completion of the international cooperative growth study, NutropinAq® European Registry (iNCGS). Front Endocrinol 2021;12:592. in Google Scholar PubMed PubMed Central

38. Wyatt, D. Lessons from the national cooperative growth study. Eur J Endocrinol 2004;151(1 Suppl):S55–9. in Google Scholar PubMed

39. Su, P-H, Yang, C, Chao, M-C, Chiang, C-L. Monitoring adherence rate to growth hormone therapy and growth outcomes in Taiwanese children using easypod connect: observational study. JMIR Pediatr Parent 2021;4:e14774. in Google Scholar PubMed PubMed Central

40. Graham, S, Weinman, J, Auyeung, V. Identifying potentially modifiable factors associated with treatment non-adherence in paediatric growth hormone deficiency: a systematic review. Horm Res Paediatr 2018;90:221–7. in Google Scholar PubMed

41. Haverkamp, F, Johansson, L, Dumas, H, Langham, S, Tauber, M, Veimo, D, et al.. Observations of nonadherence to recombinant human growth hormone therapy in clinical practice. Clin Therapeut 2008;30:307–16. in Google Scholar PubMed

42. Mohseni, S, Heydari, Z, Qorbani, M, Radfar, M. Adherence to growth hormone therapy in children and its potential barriers. J Pediatr Endocrinol Metab 2018;31:13–20. in Google Scholar PubMed

43. Blaschke, TF, Osterberg, L, Vrijens, B, Urquhart, J. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol 2012;52:275–301. in Google Scholar PubMed

44. Arnao, MDR, Sánchez, AR, López, ID, Fernández, JR, de la Vega, JAB, Fernández, DY, et al.. Adherence and long-term outcomes of growth hormone therapy with easypod™ in pediatric subjects: Spanish ECOS study. Endocr Connect 2019;8:1240. in Google Scholar

45. Dahlgren, J. Easypod™ a new electronic injection device for growth hormone. Expert Rev Med Dev 2008;5:297–304. in Google Scholar

46. Ranke, M, Guilbaud, O, Lindberg, A, Cole, T, Study, KPIG. Prediction of the growth response in children with various growth disorders treated with growth hormone: analyses of data from the Kabi Pharmacia International Growth Study. Acta Paediatr 1993;82:82–8. in Google Scholar

47. Howard, SR, Butler, GE. An analysis of the clinical and cost effectiveness of growth hormone replacement therapy before and during puberty: should we increase the dose? Horm Res Paediatr 2013;79:75–82. in Google Scholar

48. Lee, PA, Germak, J, Gut, R, Khutoryansky, N, Ross, J. Identification of factors associated with good response to growth hormone therapy in children with short stature: results from the ANSWER Program®. Int J Pediatr Endocrinol 2011;2011:6. in Google Scholar

49. Ranke, MB, Lindberg, A. Prediction models for short children born small for gestational age (SGA) covering the total growth phase. Analyses based on data from KIGS (Pfizer International Growth Database). BMC Med Inf Decis Making 2011;11:38. in Google Scholar

50. Seino, Y, Yamashita, S, Morisaki, Y, Tanaka, H, Chihara, K, Tanaka, T. Japanese growth prediction model for prepubertal children with growth hormone deficiency. J Pediatr Endocrinol Metab 2012;25:909–15. in Google Scholar

51. Loftus, J, Lindberg, A, Aydin, F, Gomez, R, Maghnie, M, Rooman, R, et al.. Individualised growth response optimisation (iGRO) tool: an accessible and easy-to-use growth prediction system to enable treatment optimisation for children treated with growth hormone. J Pediatr Endocrinol Metab: JPEM 2017;30:1019–26. in Google Scholar

52. Smyczynska, J, Hilczer, M, Smyczynska, U, Stawerska, R, Tadeusiewicz, R, Lewinski, A. Neural network models – a novel tool for predicting the efficacy of growth hormone (GH) therapy in children with short stature. Neuroendocrinol Lett 2015;36:348–53.Search in Google Scholar

53. Smyczyńska, U, Smyczyńska, J, Hilczer, M, Stawerska, R, Tadeusiewicz, R, Lewiński, A. Pre-treatment growth and IGF-I deficiency as main predictors of response to growth hormone therapy in neural models. Endocr Connect 2018;7:239–49. in Google Scholar

54. Scherdel, P, Dunkel, L, van Dommelen, P, Goulet, O, Salaün, J-F, Brauner, R, et al.. Growth monitoring as an early detection tool: a systematic review. Lancet Diabetes Endocrinol 2016;4:447–56. in Google Scholar

55. Ranke, M. The Kabi Pharmacia International Growth Study: aetiology classification list with comments. Acta Paediatr 1991;80:87–92. in Google Scholar

56. Kampstra, NA, Zipfel, N, van der Nat, PB, Westert, GP, van der Wees, PJ, Groenewoud, AS. Health outcomes measurement and organizational readiness support quality improvement: a systematic review. BMC Health Serv Res 2018;18:1–14. in Google Scholar

57. Swerdlow, AJ, Cooke, R, Beckers, D, Borgström, B, Butler, G, Carel, J-C, et al.. Cancer risks in patients treated with growth hormone in childhood: the SAGhE European cohort study. J Clin Endocrinol Metab 2017;102:1661–72. in Google Scholar

58. Savendahl, L, Cooke, R, Tidblad, A, Beckers, D, Butler, G, Cianfarani, S, et al.. Long-term mortality after childhood growth hormone treatment: the SAGhE cohort study. Lancet Diabetes Endocrinol 2020;8:683–92. in Google Scholar

59. Maghnie, M, Ranke, MB, Geffner, ME, Vlachopapadopoulou, E, Dörr, HG, Albertsson-Wikland, K, editors, et al.. Safety and effectiveness of paediatric growth hormone therapy: results from the full cohort in KIGS. Basel, Switzerland: 59th Annual Meeting of The European Society of Pediatric Endocrinology (ESPE 2021 Online); 2021:142 p.Search in Google Scholar

60. Reiter, EO, Price, DA, Wilton, P, Albertsson-Wikland, K, Ranke, MB. Effect of growth hormone (GH) treatment on the near-final height of 1,258 patients with idiopathic GH deficiency: analysis of a large international database. J Clin Endocrinol Metab 2006;91:2047–54. in Google Scholar PubMed

61. Boguszewski, MC, Lindberg, A, Wollmann, HA. Three-year growth response to growth hormone treatment in very young children born small for gestational age-data from KIGS. J Clin Endocrinol Metab 2014;99:2683–8. in Google Scholar PubMed

62. Bakker, NE, Lindberg, A, Heissler, J, Wollmann, HA, Camacho-Hübner, C, Hokken-Koelega, AC. Growth hormone treatment in children with Prader-Willi syndrome: three years of longitudinal data in prepubertal children and adult height data from the KIGS database. J Clin Endocrinol Metab 2017;102:1702–11. in Google Scholar PubMed

Supplementary Material

The online version of this article offers supplementary material (

Received: 2022-01-25
Accepted: 2022-04-19
Published Online: 2022-05-16
Published in Print: 2022-06-27

© 2022 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 8.12.2023 from
Scroll to top button